个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Yang, Yu[1,2] * ; Sun, Juxian[3] * ; Cai, Jianqiang[4] ; Chen, Minshan[5] ; Dai, Chaoliu[6] ; Wen, Tianfu[7,8] ; Xia, Jinglin[9] ; Ying, Mingang[10] ; Zhang, Zhiwei[11] ; Zhang, Xuewen[12] ; Fang, Chihua[13] ; Shen, Feng[14] ; An, Ping[15] ; Cai, Qingxian[16] ; Cao, Jingyu[17] ; Zeng, Zhen[18] ; Chen, Gang[19] ; Chen, Juan[20] ; Chen, Ping[21] ; Chen, Yongshun[22] ; Shan, Yunfeng[19] ; Dang, Shuangsuo[23] ; Guo, Wei-Xing[3] ; He, Jiefeng[24] ; Hu, Heping[25] ; Huang, Bin[20] ; Jia, Weidong[26] ; Jiang, Kexiang[27] ; Jin, Yan[28] ; Jin, Yongdong[29] ; Jin, Yun[28,31] ; Li, Gong[30] ; Liang, Yun[1] ; Liu, Enyu[32] ; Liu, Hao[33] ; Peng, Wei[7,8] ; Peng, Zhenwei[34] ; Peng, Zhiyi[35] ; Qian, Yeben[36] ; Ren, Wanhua[37] ; Shi, Jie[3] ; Song, Yusheng[38] ; Tao, Min[39] ; Tie, Jun[40,41] ; Wan, Xueying[42] ; Wang, Bin[43] ; Wang, Jin[44] ; Wang, Kai[45] ; Wang, Kang[3] ; Wang, Xin[2,46] ; Wei, Wenjing[47] ; Wu, Fei-Xiang[48] ; Xiang, Bangde[48] ; Xie, Lin[49] ; Xu, Jianming[50] ; Yan, Mao-Lin[51] ; Ye, Yufu[52] ; Yue, Jinbo[53,54] ; Zhang, Xiaoxun[7,8] ; Zhang, Yu[55] ; Zhang, Aibin[56] ; Zhao, Haitao[57] ; Zhao, Weifeng[58] ; Zheng, Xin[59] ; Zhou, Hongkun[60] ; Zhou, Huabang[25] ; Zhou, Jun[61] ; Zhou, Xinmin[62] ; Cheng, Shu-Qun[3] ; Li, Qiu[1,2] ;
机构： [1]Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China [2]Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment, Chengdu, Peoples R China [3]Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China [4]Chinese Acad Med Sci & Peking Union Med, Dept Hepatobiliary Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China [5]Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China [6]Beijing Tsinghua Changgung Hosp, Dept Radiol, Beijing, Peoples R China [7]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China [8]Sichuan Univ, West China Hosp, Liver Transplantat Ctr, Chengdu, Sichuan, Peoples R China [9]Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China [10]Fujian Med Univ, Fujian Prov Canc Hosp, Teaching Hosp, Dept Abdominal Surg, Fuzhou, Peoples R China [11]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan, Peoples R China [12]China Med Univ, Affiliated Shengjing Hosp, Shenyang, Peoples R China [13]Southern Med Univ, Sichuan Prov Peoples Hosp, Canc Ctr, Chengdu, Peoples R China [14]Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai, Peoples R China [15]Sixth Peoples Hosp Shenyang, Dept Infect Dis, Shenyang, Peoples R China [16]Southern Univ Sci & Technol, Peoples Hosp 3, Affiliated Hosp 2, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China [17]Zhejiang Univ, Sch Med, Dept Radiol, Hangzhou, Peoples R China [18]Chinese Peoples Liberat Army Gen Hosp, Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China [19]First Affiliated Hosp Anhui Med Univ, Dept Gen Surg, Hefei, Anhui, Peoples R China [20]Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Radiol, Shanghai, Peoples R China [21]Zhejiang Shuren Univ, Shulan Hangzhou Hosp, Shulan Int Med Coll, Dept Infect Dis, Hangzhou, Peoples R China [22]Wuhan Univ, Renmin Hosp, Dept Clin Oncol, Wuhan, Peoples R China [23]Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Infect Dis, Xian, Peoples R China [24]Shanxi Med Univ, Hosp 3, Shanxi Bethune Hosp, Shanxi Acad Med Sci,Dept Hepatobiliary Surg, Taiyuan, Peoples R China [25]First Affiliated Hosp Soochow Univ, Dept Hematol, Dept Gastroenterol, Shanghai, Peoples R China [26]Univ Sci & Technol China, Affiliated Hosp 1, Dept Gen Surg, USTC, Hefei, Peoples R China [27]Zhuji Peoples Hosp Zhejiang Prov, Dept Hepatobiliary Surg, Zhuji, Peoples R China [28]KMUST, Peoples Hosp Yunnan Prov 1, Dept Hepatobiliary & Pancreat Surg, Kunming, Peoples R China [29]Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Rehabil Med, Sch Med,Dept Med Oncol, Shanghai, Peoples R China [30]Beijing Tsinghua Changgung Hosp, Dept Radiat Oncol, Beijing, Peoples R China [31]Kunming Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Kunming, Peoples R China [32]Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China [33]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Canc Ctr, Chengdu, Peoples R China [34]Sun Yat Sen Univ, Beijing, Peoples R China [35]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Radiol, Hangzhou, Peoples R China [36]Anhui Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hefei, Peoples R China [37]Shandong First Med Univ, Shandong Prov Hosp, Dept Infect Dis, Jinan, Shandong, Peoples R China [38]Naval Med Univ, Dept Intervent Radiol, Shanghai, Peoples R China [39]Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China [40]University, Xijing Hosp, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China [41]Air Force Mil Med Univ, Xijing Hosp Digest Dis, Xijing Hosp, Xian, Peoples R China [42]Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Chinese Tradit Med, Shanghai, Peoples R China [43]Wuhan Univ, Renmin Hosp, Dept Hepatobiliary Surg, Wuhan, Peoples R China [44]Third Affiliated Hosp Kunming Med Univ, Yunnan Canc Hosp, Kunming, Peoples R China [45]Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Hepatobiliary Pancreat Surg Div, Nanchang, Peoples R China [46]Fifth Med Ctr Chinese PLA Gen Hosp, Dept Oncol, Beijing, Peoples R China [47]Taiyuan Peoples Hosp, Dept Gen Surg, Taiyuan, Peoples R China [48]Guangxi Med Univ, Canc Hosp, Dept Hepatobiliary Surg, Nanning, Peoples R China [49]Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Oncol, Shanghai, Peoples R China [50]Zhejiang Univ, Sch Med, Div Hepatobiliary Pancreat Surg, Beijing 310003, Peoples R China [51]Univ Sci & Technol China, Affiliated Hosp USTC 1, Hefei, Peoples R China [52]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Surg,Div Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China [53]First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China [54]Shandong Acad Med Sci, Jinan, Peoples R China [55]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Chengdu, Peoples R China [56]Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hepatobiliary Pancreat Surg, Hangzhou, Peoples R China [57]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China [58]Soochow Univ, Affiliated Hosp 1, Dept Infect Dis, Suzhou, Peoples R China [59]Xiand Jiaotong Univ, Affiliated Hosp 1, Coll Med, Xian, Peoples R China [60]First Hosp Jiaxing, Affiliated Hosp, Jiaxing Coll, Dept Hepatobiliary & Pancreat Surg, Jiaxing, Peoples R China [61]Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China [62]Air Force Med Univ, Xijing Hosp, Dept Ultrasound Med, Xian, Peoples R China
出处：
DOI： 10.1159/000541622
ISSN：

关键词： Hepatocellular carcinoma Surgery Surveillance Systemic chemotherapy Treatment

摘要：
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most HCC patients have the complications of chronic liver disease and need overall consideration and whole-course management, including diagnosis, treatment, and follow-up. To develop a reasonable, long-term, and complete management plan, multiple factors need to be considered, including the patient's general condition, basic liver diseases, tumor stage, tumor biological characteristics, treatment requirements, and economic cost. Summary: To better guide the whole- course management of HCC patients, the Chinese Association of Liver Cancer and the Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fi elds to formulate the " Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023)." Key Messages: This expert consensus, based on the current clinical evidence and experience, proposes surgical and nonsurgical HCC management pathways and involves 18 recommendations, including perioperative treatment, systematic treatment combined with local treatment, conversion treatment, special population management, symptomatic support treatment, and follow-up management. (c) 2024 The Author(s).

基金：
National Key Research and Development Program of China [2022YFC2503705]; Shanghai Municipal Health Commission [2023ZZ02005]; National Natural Science Foundation of China [82072618]

基金编号： 2022YFC2503705 2023ZZ02005 82072618

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学 1 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY Q1 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China [2]Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment, Chengdu, Peoples R China
共同第一作者：
通讯作者：
通讯机构： [1]Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China [2]Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment, Chengdu, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Yu,Sun Juxian,Cai Jianqiang,et al.Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)[J].LIVER CANCER.2024,doi:10.1159/000541622.
APA：
Yang, Yu,Sun, Juxian,Cai, Jianqiang,Chen, Minshan,Dai, Chaoliu...&Li, Qiu.(2024).Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).LIVER CANCER,,
MLA：
Yang, Yu,et al."Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)".LIVER CANCER .(2024)

相关文献

[1]Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma [2]Expression of MSP58 in hepatocellular carcinoma [3]Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model [4]Role of TGF-β in metastasis of hepatocellular carcinoma [5]Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma [6]原发性肝细胞癌合并癌性腹水的综合治疗 [7]射频消融联合治疗在肝癌治疗中应用的现状 [8]Sylvian arachnoid cyst typing and neuroendoscopic fistula surgery treatment [9]Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma [10]Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.

资源点击量：56916 今日访问量：2 总访问量：1772 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)